WebSecondary objectives included analysis of pharmacokinetic parameters, MAPK and PI3K pathway alterations, changes in tissue biomarkers, and preliminary anti-tumor efficacy. Expansion cohorts included patients with PTEN-deficient triple-negative breast cancer and endometrial cancer. WebMar 11, 2014 · BYL719 inhibited tumour growth with an I C50 of 100 ng ml −1 (BSV 154%). Model-based predictions showed potential for additional anti-tumour activity of twice daily dosing at total daily dose below 400 mg, but a loss of efficacy if administered less frequently than once daily. Conclusions
Study Assessing the Efficacy, Safety and PK of Alpelisib …
Web•An increased understanding of BYL719’s potential for anti-tumour activity was derived from a pharmacokinetic–pharmacodynamic model that described the time course of tumour … WebDec 15, 2013 · BYL719 in combination with fulvestrant shows encouraging preliminary anti-tumor activity, which supports further investigation of this combination. Recruitment … atu stuttgart vaihingen
A Study of BYL719 in Adult Patients With Advanced Solid …
WebApr 12, 2016 · Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. WebMar 11, 2014 · BYL719 is a phosphoinositide 3-kinase inhibitor (PI3Ki) in clinical development for the treatment of cancer. There are also several other PI3Kis in clinical … WebMay 20, 2013 · Le BYL-719 (alpelisib), spécifique de la p110α, a été le premier inhibiteur spécifique d'une isoforme testé chez l'homme. Dans un essai de phase I pour ce … atu sitzkissen